Investigating Immune Tolerance in Celiac Disease: AVALON Clinical Trial
VTP-1000, an investigational immunotherapy, aims to help the immune system tolerate gluten in the AVALON celiac disease clinical trial. The phase 1 trial assesses VTP-1000's safety and tolerability in adults with celiac disease on a gluten-free diet. Potential participants must be 18-65 years old, diagnosed with celiac disease within the past 10 years, and live in the US. The study, conducted across several US locations, offers compensation for time and travel. Learn more at avalon.celiac.org.
Reference News
VTP-1000, an investigational immunotherapy, aims to help the immune system tolerate gluten in the AVALON celiac disease clinical trial. The phase 1 trial assesses VTP-1000's safety and tolerability in adults with celiac disease on a gluten-free diet. Potential participants must be 18-65 years old, diagnosed with celiac disease within the past 10 years, and live in the US. The study, conducted across several US locations, offers compensation for time and travel. Learn more at avalon.celiac.org.